Updated Jul 16, 2026 · Last SEC filing 2026-06-17
enGene Therapeutics Inc. (ENGN) has filed 8 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-17. 5 Form 8-K material event filings were reported by ENGN in the last 90 days. InsiderAlpha tracks every ENGN SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001980845 |
| Form 4 filings (90d) | 8 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Latest Form 4 filing | 2026-06-17 |
All transactions sourced from SEC EDGAR Form 4 filings for enGene Therapeutics Inc. (ENGN). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Grossman William | 2 | — |
| Astley-Sparke Philip | 1 | — |
| Heffernan Michael Thomas | 1 | — |
| Zoth Lota S. | 1 | — |
| HASTINGS PAUL J | 1 | — |
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ENGN insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ENGN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.